 Dosing for first patient in PBGM01 Phase 12 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 Phase 12 clinical trials for FTD-GRN and Krabbe expected to initiate in 1H21 Completion of dedicated manufacturing suite achieved to ensure control of supply of companys lead products through early commercialization Management to host conference call today at 8:30 a.m. ET 